NCT00319267View on ClinicalTrials.gov

Bosentan in Children With Pulmonary Arterial Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

February 28, 2007

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Bosentan

Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY